期刊
OCULAR IMMUNOLOGY AND INFLAMMATION
卷 17, 期 6, 页码 403-414出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/09273940903072443
关键词
Inflammatory cytokines; intraocular inflammation; PSII; recombinant antibodies; TNF alpha; uveitis
Despite a lack of robust evidence, anti-TNF therapies are in wide use for the treatment of noninfectious ocular inflammatory diseases. There is a clear rationale, based on mechanistic and preclinical efficacy data, for their use in posterior segment intraocular inflammation. However, their increasing use for other indications has been largely extrapolated from the benefit observed in autoinflammatory and autoimmune systemic diseases. Given their cost and the potential for significant adverse events, this review highlights the evidence for their continued use, possibilities for switching anti-TNF agents, and ways of reducing the risk of therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据